Cytokinetics
Trade Cytokinetics 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About CYTK
Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility.
CYTK Key Statistics
Stock Snapshot
Cytokinetics(CYTK) stock is priced at $62.82, giving the company a market capitalization of 8.73B. It carries a P/E multiple of -8.58.
As of 2026-10-19, Cytokinetics(CYTK) stock has fluctuated between $61.50 and $63.61. The current price stands at $62.82, placing the stock +2.1% above today's low and -1.2% off the high.
The Cytokinetics(CYTK)'s current trading volume is 394.73K, compared to an average daily volume of 2.07M.
During the past year, Cytokinetics(CYTK) stock moved between $54.30 at its lowest and $88.31 at its peak.
During the past year, Cytokinetics(CYTK) stock moved between $54.30 at its lowest and $88.31 at its peak.
CYTK News
BofA lowered the firm’s price target on Cytokinetics (CYTK) to $81 from $85 and keeps a Neutral rating on the shares. The firm updated estimates ahead of Q3 ear...
Cytokinetics (CYTK) announced that Health Canada has issued a Notice of Compliance authorizing Myqorzo for the treatment of symptomatic obstructive hypertrophic...
Insiders have been trading these 5 stocks: ((CYTK)), ((INSW)), ((BJ)), ((GRCE)) and ((PBF)). Here is a breakdown of their recent trades and their value. Direct...
Analyst ratings
92%
of 24 ratingsMore CYTK News
William Blair analyst Alethia Young initiated coverage of Cytokinetics (CYTK) with an Outperform rating. Cytokinetics is a commercial-stage specialty cardiology...
Cytokinetics reported new ACACIA-HCM Phase 3 data showing aficamten significantly improved global exercise performance and multiple clinical domains in non-obst...
New insider activity at Cytokinetics ( (CYTK) ) has taken place on October 13, 2026. Cytokinetics has drawn investor attention as President & CEO Robert Blum ex...
Joseph Pantginis, an analyst from H.C. Wainwright, reiterated the Buy rating on Cytokinetics. The associated price target remains the same with $140.00. Joseph...
shares have climbed 81.2% over the past three years, helped by momentum around its heart drugs, which raises a clear question for investors. Is the current US$6...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.